Cargando…
Tumor Response, Disease Control, and Progression-Free Survival as Surrogate Endpoints in Trials Evaluating Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: Study- and Patient-Level Analyses
SIMPLE SUMMARY: How tumor response and progression-free survival (PFS) reflect the overall survival (OS) in advanced non-small cell lung cancer (NSCLC) clinical trials with immune checkpoint inhibitors (ICI) have not been clarified. This study validated the uses of objective response rate and PFS fo...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9818635/ https://www.ncbi.nlm.nih.gov/pubmed/36612179 http://dx.doi.org/10.3390/cancers15010185 |